Pricing Log in Create free account

ALX Oncology Holdings Inc. (ALXO) vs Sutro Biopharma, Inc. (STRO)

ALX Oncology Holdings Inc. and Sutro Biopharma, Inc. are both Biotechnology companies. ALX Oncology Holdings Inc. and Sutro Biopharma, Inc. are of similar size ($159.7M and $159.5M). ALX Oncology Holdings Inc. has the higher net margin (0.00% vs −395.3%) and the lower return on invested capital (−673.3% vs 0.00%). Across the 15 metrics below, ALX Oncology Holdings Inc. leads on 9 and Sutro Biopharma, Inc. on 6.

Valuation

Metric ALXO STRO Biotechnology median
P/E n/m n/m 10.60
P/S 64.54 3.49 9.40
P/B 1.16 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 13.96 0.06 9.02
Earnings yield (97.41%) (180.08%) (32.88%)
Free cash flow yield (45.06%) (91.34%) (23.13%)

Profitability

Metric ALXO STRO Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% (319.57%) 0.00%
Net margin 0.00% (395.25%) 0.00%
Free cash flow margin 0.00% (318.63%) 0.00%
Return on equity (80.65%) 266.76% (51.96%)
Return on assets (63.16%) (79.08%) (46.06%)
Return on invested capital (673.30%) 0.00% 0.00%

Growth

Metric ALXO STRO Biotechnology median
Revenue growth (TTM) — (56.25%) 6.76%
EPS growth (last fiscal year) 26.36% 24.02% 29.88%
Revenue growth, 5-year CAGR — 19.12% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALXO STRO Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 9.71 3.32 4.97
Net debt to EBITDA 0.34 0.92 1.01

Dividend

Metric ALXO STRO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALXO STRO Biotechnology median
Market cap 159.71m 159.51m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack